Conventional cancer therapies, including chemotherapy, radiotherapy, and surgical interventions, continue to face significant limitations related to poor selectivity, systemic toxicity, drug resistance, and inadequate tumor penetration. These challenges have prompted the exploration of pharmaceutical nanotechnology as a transformative approach to enhance therapeutic efficacy while minimizing adverse effects. This article aims to provide a comprehensive overview of nanotechnology-based strategies in cancer treatment, emphasizing their potential to revolutionize oncological care. Nanoparticle drug delivery systems, encompassing liposomes, polymeric nanoparticles, dendrimers, and inorganic nanocarriers, have emerged as versatile platforms capable of improving pharmacokinetic profiles and achieving controlled drug release. Passive targeting through the enhanced permeability and retention effect and active targeting via ligand-receptor interactions represent critical mechanisms for selective tumor accumulation. Additionally, tumor microenvironment-responsive systems that exploit acidic pH, elevated glutathione levels, and hypoxic conditions enable stimulus-triggered drug release at target sites. Combination therapies integrating multiple therapeutic modalities through nanotechnology platforms have demonstrated synergistic antitumor effects in preclinical models. Clinical evidence suggests that nanotechnology-based formulations substantially reduce systemic toxicity and improve treatment outcomes compared to conventional formulations. Despite these advances, clinical translation faces hurdles including scalability, reproducibility, regulatory approval pathways, and long-term safety evaluation. Future developments must address these challenges through standardized characterization protocols, improved understanding of nano-bio interactions, and innovative design strategies to realize the full potential of pharmaceutical nanotechnology in personalized cancer therapy.